University of Modena and Reggio Emilia-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

2021

  1. A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology

    European Journal of Neurology, Vol. 28, Núm. 11, pp. 3849-3855

  2. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic

    European Journal of Neurology, Vol. 28, Núm. 1, pp. 7-14

  3. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

2017

  1. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Neurology, Vol. 89, Núm. 10, pp. 1050-1059

2016

  1. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349